A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States

Background and Aim The impact of the Coronavirus disease‐2019 (COVID‐19) pandemic on patients with liver disease is not well described at the population level in the United States. We used the largest, nationwide inpatient dataset to describe inpatient liver disease outcomes in the United States dur...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2023-07, Vol.38 (7), p.1148-1157
Main Authors: Sedarous, Mary, Youssef, Michael, Adekunle, Ayooluwatomiwa Deborah, Babajide, Oyedotun, Mahmud, Muftah, Rubens, Muni, Okafor, Philip N.
Format: Article
Language:English
Subjects:
Cirrhosis
Coronaviruses
COVID-19
Disparities
Hepatitis
Hospitalization
Liver cirrhosis
Liver diseases
Liver transplantation
Mortality
Native North Americans
Pandemics
Patients
Readmissions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim The impact of the Coronavirus disease‐2019 (COVID‐19) pandemic on patients with liver disease is not well described at the population level in the United States. We used the largest, nationwide inpatient dataset to describe inpatient liver disease outcomes in the United States during the first year of the pandemic (2020) using 2018 and 2019 as comparator years. Methods Using the National Inpatient Sample (2018–2020), we explored year‐to‐year and 2020 month‐to‐month trends in hospitalizations, length of stay, and inpatient mortality for liver‐related complications including cirrhosis, alcohol‐associated liver disease (ALD) and alcoholic hepatitis using regression modeling. We reported relative change (RC) in the study period. Results Decompensated cirrhosis hospitalizations decreased in 2020 compared with 2019 (RC: −2.7%, P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.16170